Results 180 patients (median age 83; range 80–92) were identified with 313 polyps removed. The median ASA grade was 2 (range 1–4) with hypertension, COPD, Cardiac disease and Diabetes the most frequent co-morbidities. 224 (72%) polyps removed were <10 mm in size, 58 (19%) 10–19 mm, 20 (6%) >20 mm (range 20–50 mm) and size was not documented in 9 (3%). In polyps <10 mm in size, 99% had histology showing low grade or no dysplasia. 1% had high grade dysplasia (HGD) and there were no polyp cancers. For polyps 10–19 mm, histology showed low grade or no dysplasia in 81%, HGD in 14% and cancer in 5%. For polyps >20 mm; 30% (6) showed HGD and 5% (1) cancer on histology.

There were 3 (1.6%) peri-procedure complications identified (desaturation and bleeding post polypectomy) none requiring admission. 42 (23%) of the patients died within 5 years of the procedure date. The commonest causes of patient mortality were pneumonia, heart failure and stroke. CRC was the cause of death in 1 patient (0.6%) and in this case the index polypectomy was a polyp cancer.

Conclusions The rate of significant complications in patients ≥80 undergoing colonic polypectomy is low. However, mortality at 5 years is high in patients ≥80 undergoing colonic polypectomy due to co-morbid diseases other than CRC and no significant pathology is seen in diminutive (<10 mm) polyps in this age group. The number of polyps >10 mm in our cohort was small. We would recommend that polypectomy should be avoided for polyps <10 mm in patients ≥80 rather than ≥85 as previously suggested and that polypectomy of polyps >10 mm should only be considered after careful deliberation with the patient.

REFERENCES

PTh-007 CONTEMPORARY STRETTA THERAPY FOR GASTROESOPHAGEAL REFUX DISEASE IN LIGHT OF PPI CONCERN FRIEND OR FOE?

Background Gastroesophageal reflux disease (GORD) is one of the leading gastrointestinal disorders, Patients with GORD often seek alternative therapy for inadequate symptom control, with over 40% not responding to medical treatment. Current treatments include lifestyle modifications, pharmacological therapies, surgical and STRETTA therapy that is a minimally invasive procedure that significantly reduces GORD symptoms, allowing the majority of patients to eliminate or decrease use of PPIs.

Methods and patients A multi-centre retrospective data collected from three Mediclinic Middle East centres in Dubai/UAE on 73 patients, period January 2015–November 2017. Most Patients evaluated had ambulatory 24 hour pH testing and previous gastroscopy for assessment of LOS.3 patients had previous Nissen fundoplication (NF) surgery and 1 had previous gastric bypass. STRETTA uses radiofrequency (RF) energy delivered to the tissues of the distal lower Oesophageal sphincter (LOS) and gastric cardia, which decreases LOS compliance, increases LOS muscle mass, and limits the inappropriate transient LOS relaxations responsible for GORD. Patients were followed up 2 weeks, 30 days, 3 months and one year.

Results Prior DeMeester score average of 99, with hypotensive LOS pressure. There was a small learning curve (45±7 min) for the first 10 procedures; mild to moderate pain during the first 72 postoperative hours was controlled with paracetamol syrup. Two (2.5%) complications: one patient presented with ulcerative esophagitis 7 days after the STRETTA treatment, and one patient developed pneumonia 5 days postoperatively. 50 patients (63%) were off PPI dose at two months and 61 patients (77%) were off treatment at 6 months and 70 patients (88%) at 12 months. Cures were off all antisecretory medication. The other five patients (6%) were on PRN PPI.

Conclusion In our study, 88% of patients were off PPIs at one year. The rising concern of long-term side effects of the popular proton-pump inhibitors have prompted reinterest in endoscopic procedures for GORD and also economic significance as the costs of long-term pharmacological treatment are tremendous. STRETTA delivers significantly improved GORD symptoms with high efficacy and low complication rate endoscopic procedure. This procedure represents an excellent alternative for selected symptomatic gastroesophageal reflux disease patients who are intolerant of/or desire an alternative to, traditional medical therapies.

PTh-008 OUTCOMES FROM AN INTERNATIONAL MULTICENTRE HEMOSPRAY REGISTRY


1 Mediclinic City Hospital, Dubai, United Arab Emirates; 2 Gloustershire Hospitals NHS Foundation Trust, UK; 3 Horst Schmidt Kliniken, Wiesbaden, Germany; 4 Kings College London, UK; 5 Bradford Hospitals Foundation Trust, UK; 6 Governorhouse Hospitals NHS Foundation Trust, UK; 7 Royal Free Hospital, London, UK; 8 Kings College London, UK; 9 University Hospital, London, UK; 10 Royal Free Hospital, London, UK; 11 Tuckeng University Hospital, Germany; 12 University of Portsmouth, UK

10.1136/gutjnl-2018-BSGAbstracts.30

Introduction Acute gastrointestinal bleeding (AGIB) carries poor outcomes unless prompt endoscopic haemostasis is achieved. Hemospray is a novel intervention that creates a mechanical barrier over bleeding sites when applied endoscopically. Primary aim of this international prospective multicentre registry is to collect outcomes of patients with AGIB after endoscopic Hemospray application. Secondary outcomes of rebleeding, disease and procedure specific outcomes are also collected.

Method Prospective data (Jan 2016-Jan 2018) from 11 centres across UK, France and Germany collected. Hemospray used as mono therapy, dual-therapy with standard haemostatic techniques or rescue therapy once standard methods failed. Immediate haemostasis defined as cessation of bleeding within 5 min after application of Hemospray. Rebleeding defined as subsequent drop in Hb (>2 g/L), haematemeses, persistent melaena with haemodynamic compromise post therapy.